Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.907
+0.007 (0.72%)
At close: Nov 22, 2024, 4:00 PM
0.910
+0.003 (0.29%)
After-hours: Nov 22, 2024, 7:45 PM EST

Company Description

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health.

The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.

It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult.

In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates.

The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Ocugen, Inc.
Ocugen logo
Country United States
Founded 2013
Industry Biotechnology
Sector Healthcare
Employees 65
CEO Shankar Musunuri

Contact Details

Address:
11 Great Valley Parkway
Malvern, Pennsylvania 19355
United States
Phone 484 328 4701
Website ocugen.com

Stock Details

Ticker Symbol OCGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001372299
CUSIP Number 67577C105
ISIN Number US67577C1053
SIC Code 2836

Key Executives

Name Position
Dr. Shankar Musunuri M.B.A., Ph.D. Co-Founder, Chief Executive Officer and Chairman
Dr. Uday B. Kompella Ph.D. Co-founder and Independent Director
Dr. Arun Upadhyay Ph.D. Chief Scientific Officer and Head of Research and Development
Ramesh Ramachandran C.M.A., CPA, M.B.A. Chief Accounting Officer
John Kouch J.D. General Counsel
Tiffany J. Hamilton M.B.A. AVice President and Head of Corporate Communications
Kristen Craft Head of People and Culture
Michael Shine M.B.A. Senior Vice President of Commercial
Jyothy Pillai M.S. Vice President and Head of Regulatory & Quality
Dr. Huma Qamar CMI, M.D., M.P.H. Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 15, 2024 8-K Current Report
Nov 14, 2024 10-Q Quarterly Report
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 8-K Current Report
Nov 8, 2024 8-K Current Report
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 8-K Current Report
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 22, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 16, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals